Helius Medical (HSDT) Technologies announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator, PoNS, device for people with multiple sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. PoNSTEP’s key finding is that stronger adherence to PoNS Therapya, which combines non-invasive cranial nerve translingual neuro-stimulation with specific physical exercises, results in better therapeutic outcomes. The most-adherent participants maintained superior gait improvement from the end of the study’s supervised therapy phase through its unsupervised therapy phase, achieving a gain of over 6 points in their Dynamic Gait Index scores – a key clinical measurement of walking function and balance – over the first 14 weeks of the trial. PoNSTEP data also show gait improvement levels are durable, sustained at 6 months post-treatment.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue